Ori Biotech signs 10-year $120m cell-therapy manufacturing partnership

Ori Biotech has entered a 10-year commercial partnership worth up to $120 million to integrate its IRO automated manufacturing platform into production of an autologous cell therapy.

The agreement will deploy Ori's automated cell-therapy manufacturing technology across an undisclosed partner's commercial production process, supporting greater standardisation and manufacturing scalability.

The long-term contract represents a significant commercial validation of Ori's platform as cell-therapy developers seek to reduce labour, variability and production complexity in advanced-therapy manufacturing.

Field	Content
Alert Type	Deal
Companies	Ori Biotech; undisclosed cell-therapy partner
Deal Type	Long-term commercial manufacturing technology partnership
Asset or Company	IRO automated cell-therapy manufacturing platform
Therapy Area(s)	Cell therapy; advanced therapies
Technology or Modality	Automated autologous cell-therapy manufacturing
Deal Value	Up to US$120 million over 10 years
Geography	Global
What Happened	Ori Biotech entered a 10-year agreement to integrate its IRO automated manufacturing platform into an undisclosed partner's commercial autologous cell-therapy manufacturing process.
Why It Matters	Commercial-scale manufacturing remains a major constraint in cell therapy, and the agreement provides significant validation of Ori's approach to automation and standardisation.
Supporting Context	Ori's IRO platform is designed to automate and digitally manage cell-therapy manufacturing processes with the aim of reducing labour requirements, variability and manufacturing cost.
Strategic Rationale	The partner gains access to an automated production platform, while Ori secures a long-term commercial deployment of its technology.
Potential Impact	Broader automation could improve consistency, scalability and economics for commercial cell-therapy production.
Key Takeaway	Ori Biotech has secured a 10-year cell-therapy manufacturing partnership worth up to US$120 million.
What to Watch	Commercial deployment of IRO, expansion to additional manufacturing sites and evidence of improved production efficiency.
Primary Source	Ori Biotech
Relevant Date	15 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com